ResMed Streamlines Governance at Annual Meeting

The latest announcement is out from Resmed ( (RMD) ).

On November 19, 2025, ResMed Inc. held its annual meeting where significant decisions were made regarding the company’s governance and operational plans. Richard Sulpizio’s term on the board expired, leading to a reduction in board members from twelve to eleven. Additionally, stockholders approved several key proposals, including the election of eleven directors, the ratification of KPMG LLP as the independent auditor for the fiscal year ending June 30, 2026, and amendments to the 2009 Incentive Award Plan and the 2018 Employee Stock Purchase Plan. These decisions reflect ResMed’s ongoing efforts to streamline its governance and enhance its incentive structures, potentially impacting its strategic direction and stakeholder engagement.

The most recent analyst rating on (RMD) stock is a Buy with a $300.00 price target. To see the full list of analyst forecasts on Resmed stock, see the RMD Stock Forecast page.

Spark’s Take on RMD Stock

According to Spark, TipRanks’ AI Analyst, RMD is a Outperform.

Resmed’s overall stock score is driven by strong financial performance and positive earnings call outcomes. However, bearish technical indicators and a high valuation weigh on the score. The company’s strategic focus and innovation in product lines support a positive outlook, despite current market challenges.

To see Spark’s full report on RMD stock, click here.

More about Resmed

ResMed Inc. operates in the healthcare industry, focusing on the development and manufacturing of cloud-connected devices and solutions for people with sleep apnea, chronic obstructive pulmonary disease, and other chronic diseases. The company aims to improve patient quality of life and reduce the impact of chronic diseases on healthcare systems.

Average Trading Volume: 1,067,993

Technical Sentiment Signal: Buy

Current Market Cap: $35.76B

See more insights into RMD stock on TipRanks’ Stock Analysis page.